Innoplexus appoints Lawrence Ganti as CEO Americas, Silke Otte as Chief Marketing Officer and Graeme as Chief Commercial Officer

Share this News:

Mumbai. January 3, 2018. In significant addition to its leadership team, Innoplexus AG, a Frankfurt headquartered firm with offices at Pune, US and UK announced appointments of Lawrence Ganti as Chief Executive Officer – Americas, Silke Otte as Chief Marketing Officer and Graeme as Chief Commercial Officer. Innoplexus is global leader in AI based analytics as a service provider in life sciences and financial services domain.

Lawrence Ganti, who was President at Merck KGaA (Latin America) before joining Innoplexus, brings over 20 years of experience in healthcare, technology, and consumer goods. Amongst his achievements, Lawrence led the post-merger integration of Merck and Serono’s international business; implemented a turnaround of Merck’s business in India, spearheaded a transformation of the Latin America operations; and launched an award winning marketing campaign in Japan. He will be based out of New Jersey, USA.

“Lawrence is widely respected as exceptional team builder and accomplished leader in Pharma Industry. His addition to leadership team will play crucial role in our company’s transformational journey” said Dr. Gunjan Bhardwaj, Global CEO, Innoplexus.

Silke Otte brings more than 22 years of IT and financial services industry experience in digital channels, advertising, customer relationship management (CRM), campaign management, and concept development. Prior to joining Innoplexus, Silke Otte served as Chief Marketing Officer at paydirekt, where she was involved in the company building and responsible for the development of PR and marketing strategies in cooperation with the German banks and important ecommerce me-rchants. Silke will be based out of Frankfurt, Germany.

Graeme brings with him over 30 years senior management leadership and commercial experience, with in-depth understanding and reach into the healthcare market. Prior to joining Innoplexus Graeme was a senior director with QuintilesIMS having sold his Market Access company to the same in 2013. Graeme will be based out of London, UK. Innoplexus ( caters to life sciences and financial services industry offering Data as a Service (DaaS) and Continuous Analytics as a Service (CAaaS) products. It leverages Artificial Intelligence and advanced analytics to help reduce the drug development time from synthesis to approval, significantly. It uses proprietary algorithms and technologies to help global Life Sciences and Pharmaceutical organisations across all stages (Pre-clinical, clinical, regulatory and commercial) of drug development. It automates the collection, curation, aggregation and analysis, of billions of data points from thousands of data sources, using machine learning, net work analysis, ontologies, computer vision and entity normalisation.